David I. Gindler

David I. Gindler is a highly experienced patent litigator with a focus on complex intellectual property disputes, particularly within the life sciences and health technology sectors. His expertise encompasses pharmaceuticals, biotechnology, and medical devices, though his practice spans a broad array of technologies and industries. Gindler has a versatile practice, having achieved significant trial outcomes for both plaintiffs and defendants in high-stakes patent and trade secret disputes. His tracked appearances include serving as lead counsel for the defendant in DataTreasury Corporation v. NCR Corp.

Currently, Mr. Gindler serves as the Global Co-Leader of Orrick Herrington & Sutcliffe's Life Sciences & HealthTech Sector. Prior to joining Orrick, he was a partner and head of the Intellectual Property Litigation and Licensing Group at Milbank LLP. He spent a significant portion of his career at Irell & Manella LLP, where he was a managing partner and co-chair of the firm's intellectual property practice. Gindler is also notably active in Patent Trial and Appeal Board (PTAB) proceedings, where he has achieved high success rates, including defending Genentech and Biogen against 25 Inter Partes Review (IPR) petitions and securing 16 non-institution decisions.

His notable outcomes include securing a $302 million verdict for breach of a research and license agreement, as well as successfully defeating a $217 million damages claim in a patent dispute where liability had previously been established by another firm. He has represented clients such as Genentech, Biogen, and Ariosa Diagnostics in significant patent disputes.

Mr. Gindler earned his J.D. from UCLA School of Law in 1984 and a B.A. in Philosophy and Economics from Pomona College in 1981. He was admitted to the State Bar of California on June 11, 1985, and is also admitted to practice before numerous federal courts, including the Supreme Court of the United States and the Federal Circuit.